CY1124345T1 - Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι - Google Patents

Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι

Info

Publication number
CY1124345T1
CY1124345T1 CY20211100467T CY211100467T CY1124345T1 CY 1124345 T1 CY1124345 T1 CY 1124345T1 CY 20211100467 T CY20211100467 T CY 20211100467T CY 211100467 T CY211100467 T CY 211100467T CY 1124345 T1 CY1124345 T1 CY 1124345T1
Authority
CY
Cyprus
Prior art keywords
complexes
polypeptide
methods
helical
oligonucleotide
Prior art date
Application number
CY20211100467T
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124345(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc. filed Critical Replicor Inc.
Publication of CY1124345T1 publication Critical patent/CY1124345T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Αποκαλύπτεται μια φαρμακευτική σύνθεση περιέχοντας ένα σύμπλοκο χηλικής ένωσης ολιγονουκλεοτιδίων και τουλάχιστον ένα πολυπεπτίδιο ή πεγκυλιωμένο πολυπεπτίδιο. Η παρούσα αποκάλυψη περιγράφει επίσης επιπρόσθετες φαρμακευτικές συνθέσεις και μεθόδους για την αγωγή παθήσεων συμπεριλαμβάνοντας ιικές λοιμώξεις.
CY20211100467T 2012-05-18 2021-05-31 Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι CY1124345T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
CY1124345T1 true CY1124345T1 (el) 2022-07-22

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100467T CY1124345T1 (el) 2012-05-18 2021-05-31 Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι

Country Status (34)

Country Link
US (1) US9492506B2 (el)
EP (1) EP2849798B1 (el)
JP (1) JP2015517504A (el)
KR (1) KR102068109B1 (el)
CN (1) CN104349793B (el)
AU (1) AU2013262416B2 (el)
BR (1) BR112014028654A2 (el)
CA (1) CA2873529C (el)
CL (1) CL2014003134A1 (el)
CO (1) CO7131387A2 (el)
CR (1) CR20140527A (el)
CY (1) CY1124345T1 (el)
DK (1) DK2849798T3 (el)
DO (1) DOP2014000264A (el)
EA (1) EA035967B1 (el)
EC (1) ECSP14027694A (el)
ES (1) ES2873844T3 (el)
HK (1) HK1204279A1 (el)
HR (1) HRP20210840T1 (el)
HU (1) HUE054875T2 (el)
IL (1) IL235548B (el)
LT (1) LT2849798T (el)
MX (1) MX346239B (el)
MY (1) MY168778A (el)
NZ (1) NZ703095A (el)
PH (1) PH12014502551A1 (el)
PL (1) PL2849798T3 (el)
PT (1) PT2849798T (el)
RS (1) RS62030B1 (el)
SG (1) SG11201407599SA (el)
SI (1) SI2849798T1 (el)
TW (1) TWI635864B (el)
WO (1) WO2013170386A1 (el)
ZA (1) ZA201408674B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
NZ705730A (en) 2012-08-30 2016-06-24 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
HRP20231400T1 (hr) * 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
US10287583B2 (en) 2014-08-15 2019-05-14 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
EP2330194A3 (en) * 2002-09-13 2011-10-12 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
DE602004018363D1 (de) * 2003-10-27 2009-01-22 Vertex Pharma Kombinationen für die hcv-behandlung
AU2005297376A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
CA2624686A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
US7776818B2 (en) * 2005-09-29 2010-08-17 S-Cell Biosciences, Inc. Methods to treat T-cell disorders using TISF
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
WO2009076679A2 (en) 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
AU2009221064B2 (en) * 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
JP5960049B2 (ja) * 2009-05-28 2016-08-02 クルナ・インコーポレーテッド 抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
BR112012008865A2 (pt) * 2009-10-16 2019-09-24 Glaxo Group Ltd inibidores de hbv anti-sentido.
HUE029521T2 (en) * 2010-08-20 2017-03-28 Replicor Inc Oligonucleotide chelate complexes
NZ705730A (en) 2012-08-30 2016-06-24 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
DOP2014000264A (es) 2015-01-31
RS62030B1 (sr) 2021-07-30
PH12014502551B1 (en) 2015-01-21
NZ703095A (en) 2016-07-29
HUE054875T2 (hu) 2021-10-28
MX346239B (es) 2017-03-13
PT2849798T (pt) 2021-05-18
DK2849798T3 (da) 2021-05-31
IL235548B (en) 2019-07-31
CA2873529C (en) 2020-08-18
KR102068109B1 (ko) 2020-01-21
PH12014502551A1 (en) 2015-01-21
SG11201407599SA (en) 2014-12-30
EP2849798A1 (en) 2015-03-25
CA2873529A1 (en) 2013-11-21
PL2849798T3 (pl) 2021-10-18
EP2849798A4 (en) 2016-03-09
ZA201408674B (en) 2016-01-27
CO7131387A2 (es) 2014-12-01
KR20150013309A (ko) 2015-02-04
AU2013262416A1 (en) 2014-12-18
CR20140527A (es) 2014-12-15
CN104349793B (zh) 2017-11-10
EP2849798B1 (en) 2021-04-07
LT2849798T (lt) 2021-08-10
MY168778A (en) 2018-12-04
TW201408308A (zh) 2014-03-01
HRP20210840T1 (hr) 2021-08-06
TWI635864B (zh) 2018-09-21
CL2014003134A1 (es) 2015-02-13
ECSP14027694A (es) 2015-12-31
AU2013262416B2 (en) 2017-05-11
EA201401278A1 (ru) 2015-04-30
MX2014014021A (es) 2015-02-10
SI2849798T1 (sl) 2021-08-31
US9492506B2 (en) 2016-11-15
US20130309201A1 (en) 2013-11-21
ES2873844T3 (es) 2021-11-04
EA035967B1 (ru) 2020-09-07
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
WO2013170386A1 (en) 2013-11-21
JP2015517504A (ja) 2015-06-22
HK1204279A1 (en) 2015-11-13
CN104349793A (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
CY1124345T1 (el) Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι
CY1123324T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
CY1122337T1 (el) Παραγωγα σουλφamοϋλθεiοφaiνamiδιου και η χρηση αυτων ως φαρμακων για τη θεραπευτικη αντιμετωπιση της ηπατιτιδας β
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
BR112015032710A2 (pt) inibidores de bromodomínio
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
CY1122856T1 (el) Μεθοδοι χηλικου συμπλοκοy ολιγονουκλεοτιδιων
BR112017009552A2 (pt) métodos para alvejar o controle transcricional em regiões de super-realçador
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112014015582A8 (pt) compostos antivirais
CY1122418T1 (el) Αγωγη ερυθρομελαλγιας
EA201491581A1 (ru) Везикулярные композиции
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
BR112017016333A2 (pt) compostos anticâncer
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
EA201792502A1 (ru) Кабазитаксел и его применение для лечения рака
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112016020895A2 (pt) moduladores alostéricos da proteína do núcleo da hepatite b
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в